AI is transforming precision oncology—and Thermo Fisher is leading the way.
Luca Quagliata, Thermo Fisher Scientific, shared key insights at Frontiers Health:

• Moving from reactive to predictive care by integrating genomic, imaging, and clinical data to anticipate patient trajectories.
• Embedding AI into diagnostic workflows to uncover hidden mutational patterns and connect patients to optimal treatments and trials in real time.
• Making “pharmatizing AI” tangible through smart decentralized trials, accelerated drug development, and streamlined regulatory readiness.
   

Building impactful partnerships with pharma, academia, and tech leaders—including a global rollout of ChatGPT for 120,000 colleagues.